摘要
2021年8月欧洲心脏病学会提出,恩格列净成为钠-葡萄糖共转运蛋白2抑制剂中首个治疗射血分数保留的心力衰竭的药物,可明显降低心血管死亡或因心力衰竭住院风险,但其心血管获益机制尚未完全明确。本文从最新相关研究入手,探索其心血管获益可能涉及的机制。
In August 2021,European Society of Cardiology proposed that empagliflozin became the first of the sodium-glucose co-transporter 2 inhibitors for the treatment of heart failure with preserved ejection fraction,which can significantly reduce the risk of cardiovascular death or hospitalization due to heart failure,and the mechanisms of its cardiovascular benefits are not fully understood.This article starts with the latest related research to explore the possible mechanisms involved in its cardiovascular benefits.
作者
孙晓凤
王胜强
曹邦明
Sun Xiaofeng;Wang Shengqiang;Cao Bangming(Department of Clinical Medicine,Binzhou Medical University,Yantai 264003,China;Department of Cardiology,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,China)
出处
《中国心血管杂志》
2022年第2期112-116,共5页
Chinese Journal of Cardiovascular Medicine
基金
滨州医学院科研计划及科研启动基金(BY2018KYQD14)。
关键词
射血分数保留的心力衰竭
心肌细胞能量代谢
心肌微循环
钠氢交换体
细胞自噬
焦亡
Heart failure with preserved ejection fraction
Cardiomyocyte energy metabolism
Myocardial microcirculation
Sodium-hydrogen exchanger
Cellular autophagy
Pyroptosis
